These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [FGF-23 and Klotho protein - new markers in chronic kidney disease?].
    Author: Mituła I, Gołembiewska E, Ciechanowski K, Siuda A.
    Journal: Pol Merkur Lekarski; 2013 Apr; 34(202):235-8. PubMed ID: 23745333.
    Abstract:
    Disorders of calcium and phosphate metabolism are among the major problems in patients with chronic kidney disease (CKD), especially undergoing chronic dialysis. Besides the classic parathyroid-kidney axis, in recent years the existence of an endocrinological bone-kidney axis has been established, which allows better explanation of calcium and phosphate metabolism pathophysiology and secondary hyperparathyroidism in CKD. Fibroblast growth factor 23 (FGF-23) and its co-factor alpha-Klotho protein are the most important factors in the axis. The role of FGF-23 and Klotho protein, their mechanisms of action and significance in CKD have been presented. In ealy stages of CKD the increase of FGF-23 level precedes the decline in vitamin 1.25 (OH)2D3 and the increase of PTH level. Some studies showed correlation between the elevated FGF-23 level and increased mortality from cardiovascular disease in patients with chronic kidney disease. Clinical usefulness of determinations of FGF-23 and Klotho protein in chronic kidney disease is currently investigated.
    [Abstract] [Full Text] [Related] [New Search]